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Abstract
Background: The rapid progression of Coronavirus disease 2019 (COVID-19) and its
increasing burden on health systems necessitate the identification of parameters
of severe infection to help in monitoring, prognoses and development of treatment
algorithms.
Objectives: This review aims to investigate the association of lymphocyte count, CRP,
LDH, and D-Dimer with the severity of COVID-19.
Methods: This review was conducted according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases of
MEDLINE/PubMed, WHO-Virtual Health Library (VHL), and ScienceDirect were used
for the systematic search. Random effects model was used to estimate the pooled
standardized mean differences (SMD) with the corresponding 95% confidence interval
(CI), using OpenMeta Analyst software.
Results: A total of 11 studies, with 2437 COVID-19 patients, which fulfilled the eligibility
criteria were included in the meta-analysis. The analysis revealed that lymphocyte
count was significantly lower in patients with the severe form of COVID-19 (SMD =
- 1.025, P value <.001). Also, the analysis of SMD showed that patients with severe
COVID-19 have a significantly higher serum levels of CRP (SMD = 3.363, P value
<.001), D-Dimer (SMD = 1.073, P value <.001), and LDH (SMD = 3.345, P value <.001).
Conclusion: Low lymphocyte count and high levels of CRP, LDH, and D-Dimer are
associated with severe COVID-19. These laboratory markers could be used as clinical
indicators of worsening illness and poor prognosis of COVID-19.
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1. Introduction
In December 2019, Wuhan – the capital of Central China’s Hubei province – witnessed
the emergence of a new virus of the Coronaviridae family that caused several cases of
severe respiratory disease [1, 2]. The virus was named by the World Health Organization
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(WHO) as a Severe Acute Respiratory Syndrome novel Coronavirus 2 (SARS-CoV-2) and
the disease caused by this virus as Coronavirus Disease 2019 (COVID19) [1, 2]. The
disease spread dramatically and reached other provinces in China and many other
countries around the world, forcing the WHO to declare it as a global pandemic on
March 11, 2020 [3]. Despite all the efforts made to contain the disease, it has spread
to over 200 countries around the world, causing a significant burden to healthcare
facilities, as well as economic burdens on international systems [4].
The SARS-CoV-2 is transmitted by infective respiratory droplets from infected
patients, fomites, and surfaces reaching conjunctiva or respiratory mucosa. The incuba-
tion period usually ranges from 2 to 14 days after exposure, during which the patient may
be infectious [4, 5]. Animal-to-human transmission is still being investigated, knowing
that similar coronaviruses are found in bats, rodents, and birds [5, 6].
Most people infected with COVID-19 experienced a mild-to-moderate respiratory
illness, with cough and shortness of breath being the most common symptoms [6, 7].
Approximately 14% of the patients developed a severe disease with complications like
acute respiratory distress syndrome and respiratory failure, acute liver injury, acute
kidney injury, cardiovascular complications, septic shock, and multi-organ failure [6, 7].
Older people and those with underlying co-morbidities like diabetes, chronic respiratory
diseases, cardiovascular diseases, and immune-compromised patients had a higher risk
of developing severe disease [8].
Patients with severe disease or complications require special care such as admission
to intensive care units (ICU) with mechanical ventilation [9]. However, there is a wide
gap between the total population and the number of intensive care beds available [9].
Further adding to the burden, ICU services cost the hospitals around 39% of the total
drug costs, 25% of the equipment, and 13% of the lab investigations [10]. Researchers are
still working to find a definitive treatment of COVID-19, and there are ongoing trials on
some antiviral, anti-inflammatories, and anti-malarial drugs such as hydroxychloroquine
sulfate and chloroquine phosphate products to be used for certain hospitalized patients
with COVD-19 [5, 11].
Diagnosis is dependent on the evaluation of the risk of contact with an infected
patient, clinical signs and symptoms, and polymerase chain reaction testing of viral
RNA on respiratory samples [1, 4, 5]. Other investigations have been used to evaluate
the patient’s condition and to predict severe outcomes of the disease such as complete
blood count, D-Dimer, Procalcitonin, C-reactive protein (CRP), and lactate dehydroge-
nase (LDH) [4, 5]. Two recent meta-analyses showed that increased procalcitonin values
and thrombocytopenia are associated with a higher risk of severe COVID-19 [12, 13].
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Other studies suggested that lymphocytes count, D-Dimer, CRP, and LDH have a role
in the prognosis of COVID-19 [30, 31]. However, and to the best of our knowledge,
there is no meta-analysis on these biomarkers. Therefore, the objective of this review
is to assess the association between severe COVID-19 and these laboratory markers.
Taking into consideration the disease burden and the limited resources and capacities
of health facilities, it is very crucial to find parameters that support the clinical condition’s
risk assessment to aid the anticipation of severe complications.
2. Materials and Methods
2.1. Search strategy and inclusion criteria
In this meta-analysis, we followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [14]. The systematic literature search was per-
formed using the electronic databases of Medline/PubMed, WHO-Virtual health library
(VHL), and ScienceDirect, without date or language restriction. The search terms used
were “Novel coronavirus,” “2019 nCoV,” “COVID-19,” “SARS-CoV-2,” “Lymphopenia,”
“Lymphocytopenia,” “leukopenia,” “leukocytopenia,” “D-Dimer,” “C-reactive protein,”
“CRP,” “lactate dehydrogenase,” and “LDH” to ensure no possible relevant articles
were missed. Also, we reviewed the articles referenced by the identified articles in this
search.
All observational studies reporting sufficient information on lymphocyte count, CRP,
LDH, and D-Dimer levels in both severe and non-severe COVID-19 patients, with a clear
definition of severe illness, were included in the analysis for calculating the standardized
mean difference (SMD) estimates. The exclusion criteria for the study were: case reports,
editorials, letters, abstracts, and studies without sufficient data of interest. If two or more
studies had the same patient population, the study with more data was included to avoid
duplication.
The included studies determined severe COVID-19 based on the composite of res-
piratory distress with hypoxia and/or hypoxemia [15–17], the American Thoracic Society
guidelines for community-acquired pneumonia [18], Youden’s index [19], guidelines of
expert Chinese group [20], non-survival [21], disease progression [22], Oxygen sat-
uration < 90% [23], the requirement of ICU admission [24], and the requirement of
supplemental Oxygen [25].
The titles and abstracts of all articles retrieved from this search were screened for
potential inclusion in this review. Then, potentially relevant studies were reviewed (full
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text) for inclusion according to the defined eligibility criteria, and data were extracted
by independent reviewers using a data extraction form. The quality of the studies was
assessed using the Newcastle – Ottawa scale. Any disparity among the reviewers at
any step was resolved by discussion and consensus.
2.2. Data analysis
The statistical analyses were carried out using R language. The pooled SMD was
calculated from the random-effects model due to the notable heterogeneity in this meta-
analysis. Statistical heterogeneity was assessed with the I2 statistics and publication bias
was determined through Egger’s test and visual examination of the funnel plot [26].
3. Results
3.1. Characteristics of the studies
The schematic flow of the studies’ identification and selection process is presented in
Figure 1, and the summary of data from the included studies is shown in Supplementary
Table 1. Our search retrieved records for 285 published articles, of which, full texts of 34
potentially relevant studies were retrieved for full-text screening and 23 studies were
subsequently omitted because of duplication of the study populations and insufficient
data to estimate the outcomes of interest. Last, a total of 11 studies with 2,437 patients,
published from December 2019 to March 2020 were included for the analysis. All of
them were from Mainland China [16–25], while one study was based in Singapore [26].
3.2. Analysis of SMD of the lymphocyte count between the two
groups of patients
The pooled effect size showed that the lymphocyte count was significantly lower in
patients with severe COVID-19 than patients with non-severe COVID-19 and the SMD =
–1.02 (95% CI, –1.33 – –0.74: P< 0.001; Figure 2). No evidence of publication bias was
detected based on visual examination of the funnel plot and from the results of Egger’s
test (p = 0.59; Figure 6A).
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Figure 1: The flow diagram for the process of study selection and systematic review of literature.
Figure 2: Pooled SMD of lymphocyte count estimates between the two groups of patients (severe and
non-severe COVID-19).
3.3. Analysis of SMD of the CRP between the two groups
of patients
The pooled effect size showed that CRP level was significantly higher in patients with
severe COVID-19 than patients with non-severe COVID-19 with an SMD = 3.34 (95% CI,
2.19 – 4.49: P < 0.001; Figure 3). A slight publication bias was detected based on visual
examination of the funnel plot and from the results of Egger’s test (p = 0.03; Figure 6B).
The Duvall and Tweedie trim and fill method indicated that potential missing studies
were three.
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Figure 3: Pooled SMD of CRP estimates between the two groups of patients (severe and non-severe
COVID-19).
3.4. Analysis of SMD of the D-Dimer between the two groups of
patients
The pooled effect size showed that D-Dimer level was significantly higher in patients
with severe COVID-19 than patients with non-severe COVID-19, with an SMD = 1.79 (95%
CI, 1.38 – 2.19: P < 0.001; Figure 4). No evidence of publication bias was detected based
on visual examination of the funnel plot and from the results of Egger’s test (p = 0.97;
Figure 6C).
Figure 4: Pooled SMD of D-Dimer estimates between the two groups of patients (severe and non-severe
COVID-19).
3.5. Analysis of SMD of the LDH between the two groups
of patients
The pooled effect size showed that LDH level was significantly higher in patients with
severe COVID-19 than patients with non-severe COVID-19, with an SMD = 3.34 (95% CI,
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1.92 – 4.77: P < 0.001; Figure 5). No evidence of publication bias was detected based
on visual examination of the funnel plot and from the results of the Egger’s test (p =
0.83; Figure 6D). The leave-one-out sensitivity analyses indicated that our results were
robust and were not driven by any single study.
Figure 5: Pooled SMD of LDH estimates between the two groups of patients (severe and non-severe
COVID-19).
Figure 6: (A–D) Funnel plots for assessment of the publication bias.
4. Discussion
In addition to the clinical criteria, it is of great benefit to have laboratory markers
for severe infection that will help in monitoring and prognosis and will be used to
develop workup and treatment algorithms. This meta-analysis investigated the asso-
ciation between severe COVID-19 and several biomarkers. The analysis showed that
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patients with poor outcomes of COVID-19 are likely to have lymphopenia, as shown
in Figure 2. Based on several studies, it has been suggested that the immune system
is impaired during the disease and COVID-19 might damage T lymphocytes [6, 8, 27].
These studies showed a particular decrease in the CD4+ subset of lymphocytes and
higher naive CD4+ cells than memory cells in severe cases [6, 8, 27]. The higher naive
to memory cells ratio indicates that the immune system was impaired more severely
[6, 8]. The baseline lymphocyte count for these patients was not provided in these
studies to determine if the lymphopenia was disease-related or was it present prior to
the infection. If it was provided, these suggestions would have been more conclusive.
The changes in peripheral white blood cells were presumed to be caused by a
cytokine storm in the body that generates a series of immune responses [27]. The
levels of CRP and other inflammatory markers, such as IL-6, IL-8, IL-2R, and IL-10, were
noticed to be higher in severe cases than non-severe cases [21]. Increased levels of
cytokines, chemokines, and Neutrophils to Lymphocyte Ratio (NLR) in severe cases
suggest a possible hyper-inflammatory response role in the pathogenesis of COVID-19
[20]. It is perplexing how elderly persons are more prone to severe COVID-19 despite
their impaired immunity. This incongruence can be partially explained by the fact that
elderly people have impaired innate and adaptive immunity. Innate immunity in healthy
individuals manages to neutralize the virus early in the disease, keeping it from reaching
the alveoli. The situation differs in elderly patients, where the innate immunity fails to
do so, and the virus manages to reach the alveoli and replicate in high numbers. This
triggers macrophages and lymphocytes to mount a vigorous response to eradicate
virally infected cells. This response is associated with elevated levels of cytokines [28].
The D-Dimer level elevation in patients with severe disease may raise the suspicion
of underlying abnormal blood coagulation function [20]. The effect of D-Dimer widens
to include not only the correlation with the severity of the disease but also with mortality
percentage, as shown by Zhou F. et al.’s study in Wuhan, China, who found that a D-
Dimer level of > 1 mg/ml is associated with fatal outcome [21]. Gao Y. et al. showed
that the clinical benefit of D-dimer level prediction of the severity of the disease will
increase if it is combined along with IL6 level [20]. Also, the level of LDH, which is an
inflammatory marker, shows a similar correlation with mortality percentages as that of
D-dimer [19, 21]. LDH enzyme is found in the cytoplasm of all cells, thus any tissue
damage would cause an increase in the serum level of the enzyme. Different tissues
display different isoenzymes, but the isoenzymes were not specified in any of the
reviewed studies. Therefore, the origin of the LDH couldn’t be specifically identified
[29].
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The findings of this study need to be considered in the context of some limitations.
All studies we found were conducted in Asia, whereas nowadays the majority of cases
are in the United States and Europe. Due to the limitedness of the available data and
variable definition of disease severity among the studies, there is a need for further
studies to explore and clarify the prognostic role as well as the precise mechanisms
underlying the changes in these biomarkers in patients with severe COVID-19.
5. Conclusion
Lymphopenia and high levels of CRP, LDH, and D-Dimer are associated with severe
COVID-19. These laboratory markers could be used as clinical indicators of worsening
illness and poor prognosis of COVID-19. This will help in developing different algorithms
for managing COVID-19 patients according to the anticipated severity of the disease.
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Table 1 (Summary of the included studies in the review)
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